Pharmaceutical company developing specialty biopharmaceuticals for nephrology, oncology and rare diseases.
Pharmaceutical company developing specialty biopharmaceuticals for nephrology, oncology and rare diseases.
Earns from drugs it sells itself in Japan, notably in kidney disease, and from specialty medicines sold abroad such as Crysvita, a rare bone-disease antibody shared with Ultragenyx. Milestone and royalty payments from partners add to this. Kirin Holdings, the beverage group, holds the majority.
In one line: A specialty biopharma like a smaller Alexion.
Moat: narrow (IP / patents, regulatory licence). Patent-protected specialty biologics in niche therapeutic areas with high regulatory barriers.
Headquarters: Tokyo, Japan · Founded: 1949 · Employees: 5,161
Size Kyowa Kirin (4151.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $8.43B, the 163rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,552 on 18 Nov 2026.
Performance Over six months the shares gained 9.2%, against +16.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 10.4% over the last twelve months (peer median +16.2%); the operating margin is 24.3% (peer median 14.1%).
Valuation It trades at 16.4× forward earnings against a peer median of 20.8× (6th cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.5 points above its cost of capital (6.5% WACC).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥532B | ¥497B | ¥496B | ¥442B | ¥398B |
| Revenue growth | — | 0% | +12% | +11% | — |
| Gross profit | ¥389B | ¥356B | ¥351B | ¥321B | ¥301B |
| EBITDA | ¥160B | ¥128B | ¥117B | ¥117B | ¥101B |
| Net income | ¥86.1B | ¥67.0B | ¥59.9B | ¥81.2B | ¥53.6B |
| Free cash flow | ¥73.7B | ¥58.9B | ¥41.8B | ¥98.3B | ¥33.1B |
| Capital expenditure | ¥77.2B | ¥83.5B | ¥105B | ¥32.9B | ¥28.7B |
| Total debt | ¥19.5B | ¥26.1B | ¥21.7B | ¥24.2B | ¥23.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kyowa Kirin 4151.T | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% |
| Chugai Pharmaceutical 4519.T | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Daiichi Sankyo 4568.T | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% |
| Eisai 4523.T | $9.36B | +11% | +11% | 6% | 26.6× | 10.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4151.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.6% | +2.2% | 9th highest of 21 |
| 6-month return | +9.2% | +16.7% | 9th lowest of 21 |
| Distance from 52-week high | -11.1% | -13.6% | 10th highest of 21 |
| Revenue growth (TTM) | +10.4% | +16.2% | 9th lowest of 20 |
| Operating margin | 24.3% | 14.1% | 4th highest of 19 |
| Forward P/E | 16.4× | 20.8× | 6th cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -4.7% | 13.8% | 4th least demanding of 13 |
| Growth delivered (Del g) | +9.3% | +9.0% | 7th highest of 13 |
| Hurdle (Req g minus delivered) | -14.0 pp | +3.7 pp | 4th least demanding of 13 |
| ROIC minus cost of capital | +6.5 pp | +1.4 pp | 6th highest of 17 |
| EV / EBITDA | 7.0× | 22.6× | cheapest of 12 |
| Net debt / EBITDA | -1.4× | 0.0× | 4th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.25B | -7% | +9% | 3% | 6.3× | -9.7% | +7.4% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Shanghai Fosun Pharmaceutical (Group) 2196.HK | Hong Kong | $7.74B | -15% | +10% | 6% | 9.0× | 19.9% | +5.8% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Pharmaron Beijing 3759.HK | Hong Kong | $9.65B | +48% | +24% | 14% | 20.8× | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |